Your browser doesn't support javascript.
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Felip, Eudald; Pradenas, Edwards; Romeo, Margarita; Marfil, Silvia; Trinité, Benjamin; Urrea, Víctor; Hernández, Ainhoa; Ballana, Ester; Cucurull, Marc; Mateu, Lourdes; Massanella, Marta; Clotet, Bonaventura; Morán, Teresa; Blanco, Julià.
  • Felip E; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Pradenas E; Medical Oncology Department, Catalan Institute of Oncology - Badalona, Badalona Applied Research Group in Oncology (B-ARGO), Spain.
  • Romeo M; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Marfil S; Medical Oncology Department, Catalan Institute of Oncology - Badalona, Badalona Applied Research Group in Oncology (B-ARGO), Spain.
  • Trinité B; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Urrea V; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Hernández A; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Ballana E; Medical Oncology Department, Catalan Institute of Oncology - Badalona, Badalona Applied Research Group in Oncology (B-ARGO), Spain.
  • Cucurull M; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Mateu L; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Massanella M; CIBER Infectious Diseases (CIBERINFEC), Carlos III Institute of Health (ISCIII), Madrid, Spain.
  • Clotet B; Medical Oncology Department, Catalan Institute of Oncology - Badalona, Badalona Applied Research Group in Oncology (B-ARGO), Spain.
  • Morán T; Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Blanco J; Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Mol Oncol ; 17(4): 686-694, 2023 04.
Article in English | MEDLINE | ID: covidwho-2258934
ABSTRACT
Patients with solid tumors have been a risk group since the beginning of the SARS-CoV-2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post-vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA-1237 vaccine, and were compared with a group of 26 non-cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS-CoV-2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non-cancer groups were significant in individuals without previous SARS-CoV-2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non-cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS-CoV-2 vaccination programs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Mol Oncol Journal subject: Molecular Biology / Neoplasms Year: 2023 Document Type: Article Affiliation country: 1878-0261.13359

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Mol Oncol Journal subject: Molecular Biology / Neoplasms Year: 2023 Document Type: Article Affiliation country: 1878-0261.13359